/
CTMX
$3.74+$0.34 (+10.00%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$740.2M
218M shares
52-week range
$1.72 – $8.21
31% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-2.59
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $59.5M | $57.5M | $68.4M | $37.3M | $53.2M | $101.2M | $138.1M | $76.2M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $59.5M | $57.5M | $68.4M | $37.3M | $53.2M | $101.2M | $138.1M | $76.2M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $103.9M | $131.6M | $112.9M | $114.2M | $111.6M | $77.7M | $83.4M | $68.7M |
| Operating income | −$77.9M | −$110.9M | −$80.5M | −$116.0M | −$101.3M | −$6.5M | $25.0M | −$22.4M |
| EBITDA | −$76.0M | −$100.1M | −$78.0M | −$113.2M | −$96.9M | $5.5M | $33.9M | −$15.8M |
| Net income | −$84.6M | −$102.2M | −$64.8M | −$115.9M | −$99.3M | −$569.0K | $31.9M | −$17.4M |
| Net margin | -142.2% | -177.8% | -94.7% | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% |
| EPS (diluted) | -2.03 | -2.26 | -0.71 | -1.26 | -1.48 | -0.01 | 0.38 | -0.15 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $32M | $-0.42 | $-0.46–$-0.38 | 5 |
| 2027 | $34M | $-0.50 | $-0.53–$-0.45 | 5 |
| 2028 | $36M | $-0.52 | $-0.86–$-0.30 | 4 |
| 2029 | $56M | $-0.58 | $-1.21–$-0.12 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
CytomX Therapeutics, Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
www.cytomx.com- Employees
- 69
- IPO / List date
- Oct 8, 2015
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds CTMX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 2,545,260 | $8.1M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CTMX yet.
